Drug Database
ON

ondansetron (ondansetron, ODT / Zofran ODT)

✓ Approved

GSK · HTR3A · 小分子

什么是 ondansetron?

ondansetron 是一种小分子,由GSK研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名ondansetron, ODT, Zofran ODT
公司GSK
药物类别小分子
分子靶点HTR3A
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

ondansetron 作用于 1 个分子靶点:

HTR3A5-hydroxytryptamine receptor 3A (5-HT3R, 5-HT-3)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

相关研究文献

PubMedIEEE transactions on image processing : a publication of the IEEE Signal Processing Society2026-11-17

Fast and Compressed ADA-UNet: Refractive-Index Reconstruction with Latent-Domain Low-Rank Compression.

Chiang Po-Jui PJ, Lin Yu-Da YD, Yang Cheng-Hong CH

Optical diffraction tomography (ODT) provides label-free three-dimensional refractive-index (RI) maps, but conventional reconstructions are highly sensitive to speckle noise and severely under-sampled illumination angles. We propose ADA-UNet, a compact two-stage framework in which (i) a modality-specific autoencoder learns a compact representation of stitched diffraction inputs, and (ii) a latent-domain ResUNet maps these interferometric latent codes to RI latent codes for non-iterative reconstruction. For compactness, the interferometry-to-RI mapping is expressed in Dirac form, but the network itself is implemented entirely with standard convolutional operators on GPU hardware. To reduce computational cost without changing the reconstruction objective, low-rank factorization is applied specifically to the ADA-aligned latent mapper. The resulting compressed model, ADA-UNetc, reduces the parameter count from 12.5M to 6.0M (a 52% reduction) while maintaining nearly unchanged reconstruction quality, with SSIM changing from 0.943 to 0.940 and NRMSE from 0.051 to 0.052. Across all evaluated ODT, cross-modal image-synthesis, and adaptation baselines, the proposed model achieves the best overall fidelity and a measured per-volume inference time of 187 s, compared with 221-840 s for the baselines. Experiments on synthetic and real 2-D/3-D data further demonstrate robustness under evaluation-time noise perturbations and sparse-angle acquisition, highlighting the potential of ADA-UNet for efficient and reliable quantitative phase imaging.

PMID 43043740
阅读全文 →
PubMedCarbohydrate polymers2026-11-16

Boron-complexed oxidized dextran/carboxymethyl chitosan hydrogel loaded with paeoniflorin alleviates UC via TLR4-NF-κB pathway regulation and intestinal mucosal barrier restoration.

Li Shengyu S, Pan Yuting Y, Wang Gang G, Fang Jintao J et al.

Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease characterized by large-intestinal mucosal ulceration and persistent inflammation, which manifests as bloody diarrhea and abdominal pain and may elevate colorectal cancer risk. Polysaccharide-based hydrogels are attractive candidates for local rectal therapy of UC owing to favorable biocompatibility; however, their therapeutic performance is compromised by short lesion residence time caused by continuous intestinal peristalsis. Herein, we fabricated a muco-adaptive multifunctional hydrogel (B-ODT/CM@PF) constructed via dual-dynamic cross-linking of boronate-diol ester bonds and Schiff-base imine bonds for local treatment of UC. The carboxymethyl chitosan component contributes to rapid local hemostasis and epithelial barrier repair, whereas boron-complexed oxidized dextran confers broad-spectrum bactericidal capacity by disrupting bacterial membrane integrity. Benefiting from boronate-diol interactions, paeoniflorin (PF) is anchored within hydrogel networks to realize inflammation-triggered sustained release. The released PF targets the TLR4-NF-κB signaling axis to drive macrophage M2 polarization and mitigate excessive intestinal inflammatory responses. Moreover, B-ODT/CM@PF rescues the integrity of the intestinal mucosal barrier by inhibiting MLCK activation and preserving tight-junction proteins expression, further ameliorating colitis manifestations. Collectively, this dual-crosslinked bioadhesive hydrogel achieves synergistic functions including mucosal adhesion, hemostasis, antibacterial activity, immunomodulation and barrier reconstruction, providing a promising strategy for local treatment of UC.

PMID 43039541
阅读全文 →
PubMedNursing2026-11-16

Implementation of a spinal-induced hypotension management bundle for elective cesarean delivery.

Meitzner Olivia O, Klink Meghan M, McDaniel Katherine K, Wofford Kenneth K et al.

Spinal-induced hypotension (SIH) remains the most common complication associated with spinal anesthesia for cesarean delivery and may compromise maternal hemodynamic stability and uteroplacental perfusion. Evidence supports prophylactic vasopressor therapy, serotonin receptor antagonists, and optimized fluid management; however, these strategies are inconsistently applied in clinical practice. This quality improvement (QI) project evaluated the effect of a standardized SIH management bundle (SIHMB) on maternal hemodynamic outcomes. A prospective QI initiative was conducted in the obstetric operating suites of an academic medical center with a Level II trauma facility. Adult parturients undergoing elective cesarean delivery under spinal anesthesia were included. The intervention bundle consisted of intravenous ondansetron 8 mg administered 5 to 10 minutes prior to spinal anesthesia, crystalloid co-loading with 1 L of fluid during spinal placement, and prophylactic phenylephrine infusion initiated at 0.5 mcg/kg per minute. Data were collected during 12-week preimplementation and postimplementation periods. Primary outcomes included incidence and severity of hypotension. Secondary outcomes included rescue vasopressor use, antiemetic administration, and bundle adherence. This QI project was reported in accordance with the SQUIRE 2.0 guidelines for reporting QI initiatives. A total of 242 patients were included (103 preimplementation, 139 postimplementation). Implementation of the SIHMB significantly reduced the incidence of hypotension from 46% to 32% (P = .024). Mean lowest systolic and diastolic blood pressures increased significantly following implementation. Rescue vasopressor administration decreased from 72% to 49% (P < .001). Utilization of prophylactic phenylephrine infusion increased from 32% to 62%. Implementation of a standardized hemodynamic management bundle significantly improved maternal hemodynamic stability during cesarean delivery. Standardizing prophylactic strategies for SIH may enhance obstetric anesthesia safety and reduce reliance on reactive vasopressor therapy.

PMID 43038418
阅读全文 →
PubMedAllergy and asthma proceedings2026-11-14

Real-world experience with oral on-demand treatment sebetralstat for hereditary angioedema in a retrospective case series.

Lochbaum Robin R, Mohrle Raphael R, Hoffmann Thomas K TK, Greve Jens J et al.

Patients with hereditary angioedema (HAE) have unpredictable swelling attacks that can be painful and lifethreatening. Despite guidelines that recommend early on-demand treatment (ODT) for every attack, real-world adherenceremains suboptimal, partly due to treatment barriers with parenteral treatments, the only options available until 2025. The objective was to report the real-world experience with sebetralstat, the first approved oral ODT for all HAEtypes. This single-center retrospective analysis (May 2025 to February 2026) describes patient-reported reasons for switching to oral sebetralstat in 12 patients with HAE, 3 in a compassionate use program (CUP), and 9 after market authorization (October 2025), complemented by clinical outcomes and disease control in the 3 patients in CUP. The cohort included nine patients with HAE due to C1-inhibitor deficiency and three with normal C1-inhibitor HAE. Eight patients previously used subcutaneous icatibant, three used intravenous C1-inhibitor concentrate, and one used both. Reasons for switching were administration-related treatment barriers (8/12 [66.7%]), improved lifestyle compatibility(6/12 [50.0%]), and enhanced treatment autonomy (5/12 [41.7%]). The three patients in CUP initiated treatment ~20 minutes after symptom onset in 13 of 14 attacks (nocturnal facial attack: time unknown). Symptom relief occurred after ~20-30 minutes. Thirteen of 14 attacks resolved completely between 30 minutes and 4 hours after symptom relief (facial attack: 6 hours). All attacks were treated with a single 300-mg dose. No adverse events or rebound attacks were documented. Angioedema Control Test scores decreased but remained greater than or equal to 10. This initial real-world experience shows that 8 of 12 patients switched to sebetralstat because of administration-related treatment barriers, interpreted as a greater willingness to initiate oral treatment. The three patients in CUP initiatedtreatment with oral sebetralstat early for all but one attack. These preliminary findings suggest that oral administrationmay reduce barriers associated with parenteral ODT.

PMID 43025858
阅读全文 →
PubMedESC heart failure2026-11-12

Diuretic Response in Acute Heart Failure: Prediction vs Direct Measurement.

Ivey-Miranda Juan J, Cox Zachary Z, Udelson James E JE, Nunez Julio J et al.

Limited data are available informing the variability and ability to predict diuretic response (DR) longitudinally during decongestion in acute heart failure (AHF). The FASTR pilot trial compared the Reprieve System (n=52) to optimal diuretic therapy control (ODT) (n=44). The ability to longitudinally predict DR, quantified as urine output over the 72-hour intervention, was evaluated in the overall population using baseline characteristics. In the Reprieve arm, directly measured DR during the initial dose finding algorithm was also used to predict longitudinal DR. Baseline characteristics predicted only 24.7% (p<0.001) of the variance in DR over the course of IV diuretic therapy. As the duration of diuretic therapy increased, DR prediction worsened with no relationship to DR after 18 hours (p≥0.097). Directly measured DR strongly predicted subsequent urine output early (e.g., predicting 84.5% in the variance of the subsequent hour DR, p<0.001). However, this also decreased over time with modest correlation with DR at 24 hours (variance 12.7%; p=0.008) and no correlation after 48 hours (p=0.79). In the Reprieve group, serial DR measurement and diuretic titration occurred in 89% of patients eligible for further diuretic titration resulting in stable therapeutic DR over the study period despite the changes in DR over time. Accurately predicting longitudinal DR using baseline characteristics or a single direct measurement of DR is challenging as DR changes rapidly during decongestion. Due to the dynamic nature of DR over therapy, serial assessment and diuretic titration is required to longitudinally achieve therapeutic DR in most AHF patients.

PMID 43017786
阅读全文 →
PubMedMedical science monitor : international medical journal of experimental and clinical research2026-11-10

Oliceridine vs Sufentanil Combined With Ondansetron for Postoperative Nausea and Vomiting and QTc Interval in Hysteroscopic Surgery: A Prospective Randomized Controlled Study.

Guo Zhijia Z, Wu Yanan Y, Sang Yuqian Y

BACKGROUND Postoperative nausea and vomiting (PONV) is common after hysteroscopic surgery, and opioid use can raise concerns regarding cardiac safety. This prospective study aimed to compare the effects of oliceridine plus ondansetron versus sufentanil plus ondansetron on 24-hour PONV incidence and perioperative changes in the corrected QT interval (QTc) in patients undergoing non-intubated hysteroscopy under general anesthesia. MATERIAL AND METHODS In this randomized, double-blind, controlled study, 62 patients undergoing hysteroscopic surgery under general anesthesia were analyzed. Patients received propofol 2 mg/kg with either oliceridine 0.039 mg/kg plus ondansetron 4 mg (O group) or sufentanil 0.1 μg/kg plus ondansetron 4 mg (S group). The primary endpoint was 24-hour PONV. Secondary endpoints included emergence time, post-anesthesia care unit (PACU) pain scores, and change in QTc from baseline (ΔQTc) measured by 5-lead electrocardiography at predefined time points. RESULTS PONV incidence within 24 h did not differ significantly between groups (0% vs 3.2%, P>0.05). Time to anesthesia emergence was comparable between groups (P=0.960). Numerical rating scale scores at PACU discharge were also comparable (P=0.186). Repeated-measures ANOVA showed a significant time effect for ΔQTc (P=0.001), but no significant group effect (P=0.076) or group×time interaction (P=0.171). CONCLUSIONS Oliceridine plus ondansetron did not significantly reduce 24-hour PONV compared with sufentanil plus ondansetron, and this finding should be interpreted cautiously because of limited statistical power. Perioperative ΔQTc changes were minimal and similar between groups, with no clinically significant QTc prolongation.

PMID 43004669
阅读全文 →

注册免费账户还可查看另外 6632 篇文献

免费注册查看全部文献 →

了解更多ondansetron